Correspondence
Myasthenic crisis in the setting of Coronavirus Disease 2019 (COVID-19)

https://doi.org/10.1016/j.jclinane.2020.110001Get rights and content

Highlights

  • A patient with Myasthenia Gravis (MG) on immunosuppressive therapy with underlying respiratory compromise may be more susceptible to infection with COVID-19 or severe manifestations of the virus.

  • It is theorized that patients with MG may be more vulnerable to bacterial and viral infections, due to respiratory muscle weakness and use of immunosuppressive medications.

  • It is critical for practitioners to be prepared for severe respiratory compromise in patients with MG and concomitant COVID-19 superinfection.

  • In light of the COVID-19 pandemic, MG patients should be encouraged to continue their current treatment regimens, but engage in extra vigilant social distancing.

Cited by (0)

View Abstract